

Jamie M O'sullivan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2951639/publications.pdf>

Version: 2024-02-01

43
papers

1,992
citations

236612

25
h-index

276539

41
g-index

43
all docs

43
docs citations

43
times ranked

3227
citing authors

#	ARTICLE	IF	CITATIONS
1	Sialylation on O-linked glycans protects von Willebrand factor from macrophage galactose lectin-mediated clearance. <i>Haematologica</i> , 2022, 107, 668-679.	1.7	8
2	Persistent endotheliopathy in the pathogenesis of long COVID syndrome – Reply to comment from von Meijenfeldt et al.. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 270-271.	1.9	5
3	Potential mechanisms of resistance to current anti-thrombotic strategies in Multiple Myeloma. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 214-228.	0.9	1
4	Hemostatic and protein C pathway dysfunction in the pathogenesis of experimental cerebral malaria. <i>Haematologica</i> , 2022, 107, 1950-1954.	1.7	3
5	The role of VWF/FVIII in thrombosis and cancer progression in multiple myeloma and other hematological malignancies. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1766-1777.	1.9	10
6	Breast cancer cells mediate endothelial cell activation, promoting von Willebrand factor release, tumor adhesion, and transendothelial migration. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2350-2365.	1.9	18
7	Management of elective procedures in low von Willebrand factor patients in the LoVIC study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 701-710.	1.9	7
8	Advances in the Management of Cancer-Associated Thrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 139-149.	1.5	16
9	Personalized Approaches to the Treatment of Hemostatic Disorders. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 117-119.	1.5	1
10	Prolonged elevation of D-dimer levels in convalescent COVID-19 patients is independent of the acute phase response. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1064-1070.	1.9	142
11	The role of von Willebrand factor in breast cancer metastasis. <i>Translational Oncology</i> , 2021, 14, 101033.	1.7	18
12	The Biological Significance of von Willebrand Factor O-Linked Glycosylation. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 855-861.	1.5	10
13	ADAMTS13 regulation of VWF multimer distribution in severe COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1914-1921.	1.9	58
14	Illustrated State-of-the-Art Capsules of the ISTH 2021 Congress. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12532.	1.0	2
15	Persistent endotheliopathy in the pathogenesis of long COVID syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2546-2553.	1.9	208
16	Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID-19): evidence of acute and sustained endothelial cell activation. <i>British Journal of Haematology</i> , 2021, 192, 714-719.	1.2	92
17	The relationship between ABO blood group, von Willebrand factor, and primary hemostasis. <i>Blood</i> , 2020, 136, 2864-2874.	0.6	75
18	Expresser phenotype determines ABO(H) blood group antigen loading on platelets and von Willebrand factor. <i>Scientific Reports</i> , 2020, 10, 18366.	1.6	3

#	ARTICLE	IF	CITATIONS
19	More on "Association between ABO blood groups and risk of SARS-CoV-2 pneumonia"™. British Journal of Haematology, 2020, 190, 27-28.	1.2	35
20	More on COVID-19 coagulopathy in Caucasian patients. British Journal of Haematology, 2020, 189, 1060-1061.	1.2	73
21	Investigating the clearance of VWF A-domains using site-directed PEGylation and novel N-linked glycosylation. Journal of Thrombosis and Haemostasis, 2020, 18, 1278-1290.	1.9	8
22	Endothelial cells orchestrate COVID-19 coagulopathy. Lancet Haematology, the, 2020, 7, e553-e555.	2.2	122
23	Von Willebrand factor and cancer; metastasis and coagulopathies. Journal of Thrombosis and Haemostasis, 2020, 18, 2444-2456.	1.9	54
24	COVID19 coagulopathy in Caucasian patients. British Journal of Haematology, 2020, 189, 1044-1049.	1.2	307
25	Antithrombin inhibition using nanobodies to correct bleeding in hemophilia. EMBO Molecular Medicine, 2020, 12, e12143.	3.3	3
26	von Willebrand factor promotes wound healing. Blood, 2019, 133, 2553-2555.	0.6	2
27	von Willebrand factor sialylation "A critical regulator of biological function. Journal of Thrombosis and Haemostasis, 2019, 17, 1018-1029.	1.9	30
28	Advances in understanding the molecular mechanisms of venous thrombosis. British Journal of Haematology, 2019, 186, 13-23.	1.2	31
29	Advances in understanding the molecular mechanisms that maintain normal haemostasis. British Journal of Haematology, 2019, 186, 24-36.	1.2	46
30	Increased galactose expression and enhanced clearance in patients with low von Willebrand factor. Blood, 2019, 133, 1585-1596.	0.6	32
31	Blood group alters platelet binding kinetics to von Willebrand factor and consequently platelet function. Blood, 2019, 133, 1371-1377.	0.6	36
32	A novel role for the macrophage galactose-type lectin receptor in mediating von Willebrand factor clearance. Blood, 2018, 131, 911-916.	0.6	54
33	Emerging Roles for von Willebrand Factor in Cancer Cell Biology. Seminars in Thrombosis and Hemostasis, 2018, 44, 159-166.	1.5	34
34	von Willebrand factor clearance " biological mechanisms and clinical significance. British Journal of Haematology, 2018, 183, 185-195.	1.2	51
35	Significant gynecological bleeding in women with low von Willebrand factor levels. Blood Advances, 2018, 2, 1784-1791.	2.5	79
36	The Low Von Willebrand Factor in Ireland Cohort Study - Defining Optimal Management for Procedures in Patients with Low VWF (30-50 IU/dL). Blood, 2018, 132, 1178-1178.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Site-Directed Pegylation at Specific Sites Significantly Prolongs the Half-Life of A1A2A3-VWF By Markedly Attenuating LRP1-Mediated Clearance. <i>Blood</i> , 2018, 132, 1165-1165.	0.6	0
38	Plasmin Cleaves Von Willebrand Factor at K1491-R1492 in the A1A2 Linker Region in a Shear- and Glycan-Dependent Manner In Vitro. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 845-855.	1.1	29
39	Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels. <i>Blood</i> , 2017, 130, 2344-2353.	0.6	98
40	A novel role for von Willebrand factor in the pathogenesis of experimental cerebral malaria. <i>Blood</i> , 2016, 127, 1192-1201.	0.6	41
41	N-linked glycans within the A2 domain of von Willebrand factor modulate macrophage-mediated clearance. <i>Blood</i> , 2016, 128, 1959-1968.	0.6	31
42	Emerging roles for hemostatic dysfunction in malaria pathogenesis. <i>Blood</i> , 2016, 127, 2281-2288.	0.6	54
43	Altered glycosylation of platelet-derived von Willebrand factor confers resistance to ADAMTS13 proteolysis. <i>Blood</i> , 2013, 122, 4107-4110.	0.6	65